As consensus grows in Silicon Valley and Wall Street about the incoming artificial intelligence “job apocalypse,” there are few answers on what comes next. Regardless of which predictions are correct ...
The Trump Administration is underweighting the value of human health in benefit-cost analysis. Most importantly, the practice of benefit-cost analysis has been reinforced by decades of bipartisan ...
If you were to do a cost-benefit analysis of your lunch, it would be pretty difficult to do the calculation without the sandwich. But it appears that the US Environmental Protection Agency (EPA) is ...
The Social Security Administration is scheduled to start sending statements to beneficiaries, including the dollar amounts to expect for their 2026 benefits. The new year will bring a 2.8% ...
This study presents a comprehensive evaluation of the economic viability, environmental impact, and social value of valorizing metallized biaxially oriented polypropylene (BOP) film waste as a ...
Bloomberg analysis shows deflation on the ground feels more pronounced than official data show, with prices of everyday goods plunging and the share of loss-making companies at a 25-year high. Beijing ...
This is read by an automated voice. Please report any issues or inconsistencies here. “I hope this is going to be enough,” said the coordinator at Silver Lake Community Church food pantry, wiping her ...
The move — revealed in emails and internal drafts — sidelined EPA’s deep bench of career economists. The White House circumvented EPA’s career staff to write almost half of the cost-benefit analysis ...
The 2.8% Social Security cost-of-living adjustment for 2026 will push up the maximum full retirement benefit, as millions of monthly checks increase starting in January. Additionally, workers who are ...
Social Security and SSI benefits will increase by 2.8 percent in 2026 due to a cost-of-living adjustment. The average Social Security retirement benefit will increase by about $56 per month starting ...
An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in people who took Wegovy. By Dani Blum A new analysis of a major clinical trial ...
Amgen's bemarituzumab trial has taken a turn, with a final analysis showing weaker survival benefits than previously found in an earlier pre-specified interim analysis. In June, Amgen and China ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results